Axial Spondyloarthritis: Forecast in Asia-Pacific Markets to 2028
Summary:
The diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) are expected to increase from 6.1 million cases in 2018 to 8.0 million cases in 2028, at an annual growth rate (AGR) of 3.23% across the five growth markets (5GM: Australia, China [urban], India, South Korea and Japan) in the Asia-Pacific (APAC) region.
Axial Spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Axial Spondyloarthritis (AxSpA) usually starts in the third decade of the life, and can have a major impact on patient health-related quality of life and work productivity.
Axial Spondyloarthritis (AxSpA) is an insidious disease and difficult to diagnose. Diagnosis is aided by family history, clinical examination, C-reactive protein (CRP), HLA-B27 testing and radiographic imaging. Diagnoses of Axial Spondyloarthritis (AxSpA) patients have an average delay of eight years from the onset of symptoms.
Of the 5GM (Australia, China [urban], India, South Korea and Japan), China (urban) is expected to have the highest number of diagnosed prevalent cases, increasing from 3.1 million cases in 2018 to 4.1 million cases in 2028. There were 2.8 million cases in India while Australia had 0.08 million diagnosed prevalent cases in 2018. The major drivers for the upward trend in the diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) in the 5GM (Australia, China [urban], India, South Korea and Japan) over the next decade is partly attributable to aging population combined with the increasing trend in the prevalence of the condition.
The latest report, “Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028”, provides an overview of the risk factors and historical trends for Axial Spondyloarthritis across the 5GM (Australia, China [urban], India, South Korea and Japan) in the ages ≥18 years.
Scope:
Reasons to buy:
The report will enable you to:
Summary:
The diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) are expected to increase from 6.1 million cases in 2018 to 8.0 million cases in 2028, at an annual growth rate (AGR) of 3.23% across the five growth markets (5GM: Australia, China [urban], India, South Korea and Japan) in the Asia-Pacific (APAC) region.
Axial Spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Axial Spondyloarthritis (AxSpA) usually starts in the third decade of the life, and can have a major impact on patient health-related quality of life and work productivity.
Axial Spondyloarthritis (AxSpA) is an insidious disease and difficult to diagnose. Diagnosis is aided by family history, clinical examination, C-reactive protein (CRP), HLA-B27 testing and radiographic imaging. Diagnoses of Axial Spondyloarthritis (AxSpA) patients have an average delay of eight years from the onset of symptoms.
Of the 5GM (Australia, China [urban], India, South Korea and Japan), China (urban) is expected to have the highest number of diagnosed prevalent cases, increasing from 3.1 million cases in 2018 to 4.1 million cases in 2028. There were 2.8 million cases in India while Australia had 0.08 million diagnosed prevalent cases in 2018. The major drivers for the upward trend in the diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) in the 5GM (Australia, China [urban], India, South Korea and Japan) over the next decade is partly attributable to aging population combined with the increasing trend in the prevalence of the condition.
The latest report, “Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028”, provides an overview of the risk factors and historical trends for Axial Spondyloarthritis across the 5GM (Australia, China [urban], India, South Korea and Japan) in the ages ≥18 years.
Scope:
- Overview of axSpA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized axSpA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the axSpA therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the Asia-Pacific axSpA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy:
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Asia-Pacific axSpA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Asia-Pacific axSpA therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the Asia-Pacific axSpA therapeutics market from 2018-2028.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Axial Spondyloarthritis: Executive Summary
2.1 Axial Spondyloarthritis Market to Experience Mild Growth from 2018-2028
2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves
2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period
2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Axial Spondyloarthritis Pipeline
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
5.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
5.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario
5.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Alternative Scenario
5.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients
5.5 Epidemiological Forecast for AS and Nr-axSpA (2018-2028) - Base Scenario
5.5.1 Diagnosed Prevalent Cases of AS
5.5.2 Diagnosed Prevalent Cases of Nr-axSpA
5.6 Epidemiological Forecast for AS and Nr-axSpA (2018-2028) - Alternative Scenario
5.6.1 Diagnosed Prevalent Cases of AS
5.6.2 Age-Specific Diagnosed Prevalent Cases of AS
5.6.3 Sex-Specific Diagnosed Prevalent Cases of AS
5.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity
5.6.5 Diagnosed Prevalent Cases of Nr-axSpA
5.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-axSpA
5.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA
5.7 Discussion
5.7.1 Epidemiological Forecast Insight
5.7.2 Limitations of the Analysis
5.7.3 Strengths of the Analysis
6 Disease Management in APAC
6.1 Diagnosis and Treatment Overview
6.2 India
6.3 China
6.4 Australia
6.5 South Korea
6.6 Japan
7 Competitive Assessment
8 Unmet Needs and Opportunity Assessment in APAC
9 Current and Future Players in APAC
10 APAC Markets
11 Appendix
List of Tables
Table 1: Axial Spondyloarthritis: Key Metrics in the 5GM
Table 2: Risk Factors and Comorbidities for AS
Table 3: Treatment Guidelines for AxSpA
Table 4: Country Profile - India
Table 5: Country Profile - China
Table 6: Country Profile - Australia
Table 7: Country Profile - South Korea
Table 8: Country Profile - Japan
Table 9: Leading Treatments for Axial Spondyloarthritis, 2020
Table 10: Average Percent Discount on Biosimilars Compared to Biologic Reference Products Across the 5GM, 2019
Table 11: AbbVie’s AxSpA Portfolio Assessment, 2020
Table 12: Pfizer’s AxSpA Portfolio Assessment, 2020
Table 13: J&J’s AxSpA Portfolio Assessment, 2020
Table 14: UCB’s AxSpA Portfolio Assessment, 2020
Table 15: Novartis’ AxSpA Portfolio Assessment, 2020
Table 16: Eli Lilly’s AxSpA Portfolio Assessment, 2020
Table 17: Kyowa Hakko Kirin’s AxSpA Portfolio Assessment, 2020
Table 18: Axial Spondyloarthritis Market - APAC Drivers and Barriers, 2018-2028
Table 19: Key Events Impacting Sales for Axial Spondyloarthritis in India, 2018-2028
Table 20: Axial Spondyloarthritis Market - Drivers and Barriers in India, 2018-2028
Table 21: Key Events Impacting Sales for Axial Spondyloarthritis in China, 2018-2028
Table 22: Axial Spondyloarthritis Market - Drivers and Barriers in China, 2018-2028
Table 23: Key Events Impacting Sales for AxSpA in Australia, 2018-2028
Table 24: AxSpA Market - Drivers and Barriers in Australia, 2018-2028
Table 25: Key Events Impacting Sales for Axial Spondyloarthritis in South Korea, 2018-2028
Table 26: AxSpA Market - Drivers and Barriers in South Korea, 2018-2028
Table 27: Key Events Impacting Sales for Axial Spondyloarthritis in Japan, 2018-2028
Table 28: AxSpA Market - Drivers and Barriers in Japan, 2018-2028
Table 29: Key Historical and Projected Launch Dates for Axial Spondyloarthritis
Table 30: Key Historical and Projected Patent Expiry Dates for Axial Spondyloarthritis
Table 31: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in Axial Spondyloarthritis During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That The Publisher Expects to Be Licensed for the Treatment of Axial Spondyloarthritis During the Forecast Period
Figure 4: Pathogenic Mechanisms of Axial Spondyloarthritis
Figure 5: 5GM, Diagnosed Prevalence (%) of AxSpA, Both Sexes, Ages ≥18 Years, 2008-2028 - Base Scenario
Figure 6: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Base Scenario
Figure 7: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario
Figure 8: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Alternative Scenario
Figure 9: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-axSpA - Alternative Scenario
Figure 10: 5GM, Sources Used, HLA-B27 Seropositivity Data Among the Diagnosed Prevalent Cases of AS - Alternative Scenario
Figure 11: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 - Base Scenario
Figure 12: 5GM, Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, Both Sexes, N, 2018 - Base Scenario
Figure 13: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 14: 5GM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2018 - Alternative Scenario
Figure 15: 5GM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥18 Years, N, 2018 - Alternative Scenario
Figure 16: 5GM, Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 17: 5GM, Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 18: 5GM, Age-Specific Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, N, 2018 - Alternative Scenario
Figure 19: 5GM, Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, N, 2018 - Alternative Scenario
Figure 20: Flowchart of the Diagnosis and Management of Axial Spondyloarthritis
Figure 21: Unmet Needs and Opportunities in AxSpA
Figure 22: Overview of the Development Pipeline for AxSpA
Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that The Publisher Expects to Be Licensed for AxSpA in the Five Growth Markets in Asia-Pacific During the Forecast Period
Figure 24: Competitive Assessment of the Late-Stage Pipeline Agents that The Publisher Expects to Be Licensed for the Treatment of AxSpA in the Five Growth Markets in Asia-Pacific During the Forecast Period
Figure 25: Analysis of the Company Portfolio Gap in AxSpA in the 5GM, During the Forecast Period
Figure 26: APAC (5GM) Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028
Figure 27: Sales Forecast by Class for Axial Spondyloarthritis in India in 2018 and 2028
Figure 28: Sales Forecast by Class for Axial Spondyloarthritis in China in 2018 and 2028
Figure 29: Sales Forecast by Class for Axial Spondyloarthritis in Australia in 2018 and 2028
Figure 30: Sales Forecast by Class for Axial Spondyloarthritis in South Korea in 2018 and 2028
Figure 31: Sales Forecast by Class for Axial Spondyloarthritis in Japan in 2018 and 2028
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Novartis
- UCB
- Janssen
- Eli Lilly
- Pfizer
- Kyowa Hakko Kirin
